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EFFECTS OF APOB-DERIVED PEPTIDE VACCINATION IN A MURINE 
MODEL OF SYSTEMIC LUPUS ERYTHEMATOSUS  
BRIAN TUAN SAMUELSEN 
ABSTRACT 
 Objective: Atherosclerotic disease progression is mediated in part, by 
immunological mechanisms. In recent years, interest has increased towards the 
prospect of modulating these immune mechanisms through vaccination to 
ameliorate the course of disease. Patients with lupus are at a significantly higher 
risk for accelerated atherosclerosis and related complications. The goal of this 
study was to assess the outcome of immunization in mouse models of lupus, and 
lupus with accelerated atherosclerosis. 
Materials/Methods: Atherosclerosis-prone apoE-/- mice and autoimmune 
gld mice were previously crossed to generate the gld.apoE-/- mouse. Mice were 
treated with an apoB-100-derived vaccine, Alum (adjuvant control), or PBS 
control. The antibody response was determined by quantifying the amount of 
circulating anti-apoB100. Serum triglyceride and cholesterol levels were 
analyzed. Kidney tissue from gld and gld.apoE-/- mice was processed and 
histologically analyzed, using glomerular tuft size as a measure of renal disease 
and by extension, autoimmune disease severity. 
Results: Immunization led to a pronounced initial antibody response that 
was decreased by the endpoint of the study. No significant differences in serum 
	  	   vi	  
triglyceride or cholesterol were observed regardless of treatment. Similarly, no 
significant differences were observed in glomerular tuft size.  
Conclusion: The data suggests that immunization with an apoB-100- 
derived vaccine neither improves nor worsens autoimmune disease severity in 
the gld.apoE-/- mouse model. It also appears that immunization is tolerated in the 
autoimmune background. While further study is necessary to determine the 
efficacy of immunization in reducing atherosclerotic disease in this model, this 
may be a possible therapy to lower incidence of atherosclerosis in lupus patients.  
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INTRODUCTION 
Atherosclerosis 
Atherosclerosis is a chronic disease characterized by the development of 
lesions and plaque on the inner intimal layer of the arterial walls. It is the primary 
cause of cardiovascular disease, a public health risk of widespread prevalence. 
Cardiovascular disease is the single largest cause of death among people in 
industrialized countries (Braunwald, 1997). In 2010, cardiovascular disease was 
the cause of 25% of deaths globally, increasing from 20% in 1990 (Lozano, 
2012). 
Certain regions along arteries are at a substantially higher risk of 
developing atherosclerotic lesions owing to shear stress and the particular 
hemodynamics of blood flowing along those regions (Dai, 2004). Structurally, 
these atherosclerotic lesions form a thickening of the arterial intima. Their cores 
are composed of lipids and foam cells, which are lipid-laden macrophages. Outer 
layers contain fibrous connective tissue, smooth muscle cells, and immune cells 
including macrophages, T cells, and dendritic cells (Stary, 1995). Lesion 
development is chronic in nature and often quiescent for decades. Rupture of the 
plaque cap is the classical end-disease event and exposes the contents of the 
lesion to the blood, forming a thrombus that can lead to myocardial infarction 
(Hansson, 2005). The initiation and progression of lesions are a consequence of 
both endothelial injury and the immune response of the body to that injury.  
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High levels of low-density lipoprotein (LDL) cholesterol in the blood are 
one of the major risk factors for atherosclerosis (Ross, 1999). While wild-type 
laboratory mice do not tend to develop atherosclerosis, mice deficient for 
apolipoprotein E (apoE) have pronounced hypercholesterolemia and are highly 
prone to developing spontaneous atherosclerotic lesions (Hansson, 2005). One 
of the main initiators of injury, along with aforementioned shear stress, is the 
response of immune cells to the accumulation of modified LDL phospholipids in 
the vessel wall (Leitinger, 2003). Regions of the arterial intima at risk of 
atherosclerosis allow LDL molecules to adhere to and permeate the endothelium 
(Tabas, 2007). Once retained in the endothelium, the LDL molecules are more 
vulnerable to oxidation than they were in the bloodstream (Schwenke, 1989). A 
variety of mechanisms leading to LDL oxidation have been explored, but a 
complete mechanistic picture has not been definitively established. One 
candidate enzymatic mechanism is 2/15-lipoxygenase which is expressed on 
monocytes. Mice deficient in the L-12LO allele of 2/15 lipoxygenase crossed to 
the atherosclerosis-prone apoE-/- background display diminished atherosclerosis 
(Cyrus, 1999). Another enzyme with a putative role in LDL oxidation is 
myeloperoxidase, which is present in atherosclerotic plaques and acts to modify 
LDL molecules to increase their uptake by macrophage scavenger receptors 
(Daugherty, 1994) (Podrez, 2000). 
Investigation into the initial injury events in atherosclerosis has pointed 
towards oxidized LDL (oxLDL) and a variety of related oxidized phospholipids 
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(oxPL) as players in proatherogenic signaling pathways. The activation of 
immune pathways involves the recognition of oxPL and other pathogens by 
several innate immune system receptors including toll-like receptors and CD36 
receptors expressed on macrophages and dendritic cells (Miller, 2003) (Podrez, 
2002). The role of these receptors in the progression of atherosclerosis is 
supported by the amelioration of atherosclerosis in apoE-/- mice with toll-like 
receptor deficiency (Björkbacka, 2004). Activated macrophages, that are often 
found in conditions of atherosclerosis, produce cytokines and chemokines, such 
as interleukin-1β and macrophage colony-stimulating factor, that contribute to the 
progression of the inflammatory response (Moore, 2011). Additionally, oxLDL 
induces endothelial cells to increase expression of adhesion molecules such as 
vascular cell adhesion protein 1 (VCAM-1), resulting in increased recruitment of 
monocytes and lymphocytes to the site of the lesion (Hansson, 2005) (McMurray, 
1993). 
Another type of cell important in lesion development is the T cell. Upon the 
presentation of antigens by the innate immune system, T cells specific to those 
antigens are recruited and activated. CD4+ T cells preferentially differentiate into 
Th1 cells after binding to adhesion molecules or antigens presented by major-
histocompatibility-complex molecules at the lesion site. Th1 cells have a largely 
pro-inflammatory cytokine profile and produce interferon-γ (IFN- γ), interleukin-2 
(IL-2), tumor necrosis factor alpha (TNF-α), and tumor necrosis factor beta (TNF-
β) (Szabo, 2003). In atherosclerotic lesions, IFN –γ and IL-2 in particular act to 
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spur a downstream inflammatory response (Frostegård, 1999). Anti-inflammatory 
immune response players also act at lesion sites. One of the mediators of the 
anti-inflammatory response is the cytokine interleukin-10 (IL-10), released by Th2 
type cells. (Mallat, 1999) Another T cell type that may play a role in lesion 
development is the regulatory T cell population, which are Foxp3+ CD8+CD25+. In 
an attempt to determine whether their presence in lesions contributed to 
atherosclerosis, these cells were introduced into apoE-/- mice which led to 
diminished atherosclerotic disease (Zhou, 2014).  
Evidence of beneficial modulation of atherosclerosis has been 
demonstrated by the immunoglobulin M (IgM) antibody released by B cells. Upon 
B cell recognition of a specific antigen, the less specific IgM antibody is initially 
released as a primary response. As time progresses, IgM production wanes and 
a larger secondary response of the more specific immunoglobulin G (IgG) 
antibody production begins (Eales, 2005). In a cross of LDL receptor-deficient 
(Ldlr-/-) and IgM deficient mice, considerably worse atherosclerotic disease was 
observed (Lewis, 2009). A separate study reported that polyclonal IgM injected 
into apoE-/- mice in the final 4 weeks of a hypercholesterolemic diet mitigated 
lesion formation, while monoclonal IgM did not. This suggests that different B cell 
populations may have varying capabilities of exerting atheroprotective effects 
(Cesena, 2009). Both IgM and IgG antibodies against oxLDL have been 
observed in atherosclerotic disease. It has been reported that neither IgM nor 
IgG autoantibodies were independent predictors of cardiovascular disease, 
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although there was some evidence to suggest that higher IgM levels might have 
a protective effect (Ravandi, 2011). Overall, the progression of atherosclerotic 
plaques likely represents a shift in balance towards pro-inflammatory and pro-
atherogenic factors. 
 
Modulation of Atherosclerosis with Vaccines 
Because of the crucial role inflammation plays in atherosclerosis, efforts 
have attempted to modulate the immune system via vaccination to mitigate the 
development of atherosclerosis. OxLDL particles, with their integral contribution 
to atherosclerotic lesions, are an obvious candidate for a vaccine target. Early 
efforts at immunizing rabbits with oxLDL possessing malondialdehyde-modified 
(MDA) lysine epitopes were successful in decreasing atherosclerosis, (Palinski, 
1995). However, more work is required to determine which component of oxLDL, 
a complex molecule, could potentially be translated into an effective vaccine. 
Further research has demonstrated that the specific antigen in oxLDL that elicits 
an immunogenic response is a particular peptide sequence of the Apolipoprotein 
B-100 (apoB-100) protein (Fredrikson, Söderberg, 2003).  
ApoB-100 is a component of LDL, intermediate density lipoproteins, and 
very low density lipoproteins. ApoB-100 is the critical signaling component 
between LDL molecules and their receptors (Walldius, 2004), making it integral in 
the initial permeation of arterial walls. Proteoglycan matrix proteins have been 
implicated in binding to the apoB-100 component of LDL, which facilitates 
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subendothelial accumulation of LDL. Transgenic mice generated with impaired 
apoB-100 proteoglycan binding display reduced atherosclerosis (Skålén, 2002). 
Taken together, evidence suggests that apoB-100 plays an important role in the 
development of atherosclerotic lesions. 
The antigen component, designated as p210, is a surface epitope of 
apoB-100. Immunization with p210 in mice resulted in a protective effect against 
atherosclerosis (Chyu, 2005). The mechanism by which p210 immunization 
reduces atherosclerosis is unclear but work over the past decade has delivered 
some insights. An increase of CD8+ T cells in immunized mice has been noted; 
CD8+ cells taken from immunized mice and administered to non-immunized mice 
led to a transfer of protective effects of immunization. Additionally, CD8+ T cells 
were found to lower the count of dendritic cells at lesion sites (Chyu, 2012). 
Dendritic cells present antigens to lymphocytes, and play a role in lipid uptake 
and foam cell formation in atherosclerosis-prone regions of arteries, therefore 
(Paulson, 2009), this may represent a potential mechanism by which p210 
modulates atheroprotective effects. 
Pertinent to the prospect of modulating the immune response to apoB-100 
for the purposes of vaccination, is characterizing the native immune response to 
apoB-100 in humans. In a population study testing an apoB-100 polypeptide 
library, native apoB-100 and MDA-modified apoB-100 elicited dichotomous 
antibody responses. IgM displayed significantly less binding to the MDA-modified 
apoB-100 compared to native ApoB-100. Administration of the apoB-100 vaccine 
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demonstrated a more pronounced IgM response than the IgG response against 
MDA-modified apoB-100 (Fredrikson, Hedblad, 2003). In a more recent study 
examining a larger population, levels of IgM against MDA-modified apoB-100 
(IgM-p210MDA) and levels of IgG against natural apoB-100 p210 (IgG-p210nat) 
were measured against changes in carotid intima-media thickness (cIMT). IgM-
p210MDA was inversely correlated with cIMT progression. IgG-p210nat was initially 
associated with lower levels of cIMT, but adjusting for traditional atherosclerotic 
risk factors abolished those associations (McLeod, 2014). Based on these 
findings, it is reasonable to suggest a native atheroprotective role for IgM against 
apoB-100 that may be augmented after immunization using apoB-100.  
 
Systemic Lupus Erythematosus 
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease 
with a variety of manifestations in various organs and tissues. Autoimmune 
dysfunction results in a heterogeneous course and range of symptoms, severity, 
and specific organ system involvement in different patients. Several genes and 
environmental factors have been implicated in contributing to the risk of SLE but 
the exact mechanisms of its etiology remain to be elucidated (Tsokos, 2011). 
Epidemiologically, disease incidence and prevalence is about ten times higher in 
women than men across most populations. Mortality risk is higher for SLE 
patients as compared to the general population, with the predominant causes of 
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death including kidney disease, infection stemming from immunosuppressive 
therapy, and cardiovascular disease (Bernatsky, 2006). 
Mechanistically, several components of the adaptive and innate immune 
systems interact in the pathology of SLE. T cells in SLE have lower thresholds for 
activation and experience impaired signaling at their T cell receptor. This leads to 
the over- and under-expression of various genes which have the potential to 
increase inflammation (Kyttaris, 2007). Another effect of dysfunctional T cells in 
SLE is the upregulated production of IgG antibodies by autoreactive B cells 
(Crispín, 2008). The production of anti-double-stranded DNA antibodies that 
complex to the patient’s own DNA leads to a deleterious effect on organs and 
tissues. (Crispín, 2010) Anti-double stranded DNA complexes were found to 
localize in glomerular basement membranes, suggesting that they may be 
targeted by complement and lead to lupus nephritis (Van Bruggen, 1997). 
Defective apoptotic signaling and impaired clearance of necrotic cellular debris in 
SLE also contributes to immune autoreactivity. Increased exposure to 
autoantigens diminishes self-tolerance by the immune system and can lead to 
increased autoreactivity and inflammation (Munoz, 2005). 
 
Atherosclerosis in Systemic Lupus Erythematosus 
Female patients with SLE have up to a 50-fold higher risk of myocardial 
infarction than those in comparable populations without SLE (Manzi, 1997). 
Since the 1970s, survival rates for SLE patients have improved with the notable 
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exception of deaths due to cardiovascular disease, which has increased over that 
time (Pons-Estel, 2010). The accelerated progression of atherosclerotic disease 
in SLE patients, independent of traditional atherosclerotic risk factors except 
aging, has been identified as the main cause of increased risk of cardiovascular 
disease events (Roman, 2007). Renal disease has been marked as a potential 
risk factor for atherosclerosis in SLE patients (Sule, 2011). An association has 
been identified between SLE disease severity and the extent of plaque 
development and coronary artery disease (McMahon, 2014). Therefore, the 
mechanism by which SLE contributes to atherosclerosis is unclear, but it is likely 
that many of the autoimmune and inflammatory mediators contributing to 
atherosclerosis may also be involved in SLE. 
Mouse models generated by crossing atherosclerosis-prone phenotypes 
with autoimmune-prone phenotypes have demonstrated that the combination of 
disease states exacerbates the severity of both. Some of these phenotypes 
include gld.apoE-/-, LDLr -/-.apoA-I -/-, and Sle.16/LDLr -/- mice (Aprahamian, 2004; 
Wilhelm, 2009; Lewis, 2012). Of the several proposed components to 
mechanism related to this thesis, it is possible that the autoimmune and 
inflammatory environment established by SLE may contribute to proatherogenic 
processes, potentially by increasing the propensity for endothelial activation or 
injury. Activation of endothelial cell expression of adhesion molecules has been 
observed in serum samples of SLE patients with active disease (Janssen, 1994). 
In addition, a study of otherwise healthy patients post-myocardial infarction 
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demonstrated increased circulating apoptotic particles compared to patients with 
non-coronary heart disease (Mallat, 2000).  
Other players in SLE autoreactivity have also been investigated in relation 
to atherosclerosis. High-density lipoprotein (HDL) performs reverse transport of 
cholesterol throughout the body. In addition to its ability to clear cholesterol, HDL 
is thought to exert an atheroprotective effect by blocking the oxidation of LDL. It 
putatively accomplishes this through its antioxidative enzyme paraoxanase, 
which has lowered activity in SLE patient populations (Alves, 2003). Anti-HDL 
antibodies have been observed in lupus patients and may represent a pathway 
by which SLE leads to increased oxidation of LDL and uptake by monocytes 
(O’Neill, 2010). In addition, states of chronic inflammation can induce HDL to 
switch to assuming a proatherogenic function and oxidize LDL (Lenten, 1995).  
Although anti-oxLDL antibody blood levels also rise with SLE disease 
activity, a consensus has not been reached on their direct contribution to 
atherosclerosis (Vaarala, 2000). Along with anti-oxLDL antibodies, several other 
SLE antibodies including anti-phospholipid antibodies and anti-endothelial cell 
antibodies are considered markers of atherosclerotic risk but whether they are 
atheroprotective or atherogenic has not been concluded (Narshi, 2010). 
 
Objectives  
Our study set out to assess the impact of immunization with the apoB 
p210 peptide in murine models of,SLE (gld), SLE with associated atherosclerosis 
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(gld.apoE-/-), and atherosclerosis (apoE-/-) as a control. While apoB p210 has 
been extensively studied in atherosclerosis progression in hyperlipidemic animal 
models, it has not been explored in the context of lupus or lupus-associated 
atherosclerosis. It is important to note that immunization of the general populace 
would not be advisable. However, immunization to ameliorate or limit 
atherosclerosis in a specialized patient population with accelerated 
cardiovascular disease risk such as lupus is a treatment worth exploring. It is 
also possible that beneficial effects on lupus disease could occur secondary to 
the modulation of the immune response to atherosclerosis. We hypothesized that 
treatment with the apoB peptide-based vaccine would lessen autoimmune 
mediated damage. This thesis utilized colorimetric assays to assess the impact 
of apoB p210 immunization on total serum levels of both cholesterol and 
triglyceride. ELISA tests for IgM and IgG measured the antibody response to 
immunization over time. Finally, the effect of immunization on SLE disease 
severity was assessed through histological observation of kidney health. 
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METHODS  
Animals  
ApoE-/- mice with an atherosclerotic phenotype and gld mice with a lupus-
like phenotype were purchased from Jackson Laboratory. ApoE-/- and gld mice 
were crossed at Boston University School of Medicine to breed gld.apoE-/- mice 
harboring a phenotype of accelerated atherosclerosis and lupus. At 7 weeks of 
age, mice were administered a primary immunization of 200µL apoB-100 peptide 
by subcutaneous injection to the dorsal area. Booster shots were subsequently 
administered at 10 and 12 weeks of age. Control groups were given either PBS 
or Alum (adjuvant) injections. Gld mice were fed a normal chow diet. apoE-/- mice 
were fed a high cholesterol Western diet (TD 88137, Harlan-Teklad, 0.20% 
cholesterol, 21% fat). Gld.apoE-/- mice received a normal chow diet for the 
duration of the study or were switched to a high cholesterol Western diet at 13 
weeks of age. Small blood samples were collected by tail vein at the midpoint of 
the study, and all mice were sacrificed at 25 weeks of age. All mouse 
experiments were performed under protocol approved by the Institutional Animal 
Care and Use Committee of Boston University School of Medicine. 
 
Serum Cholesterol and Triglyceride Assays  
Serum cholesterol was quantified by colorimetric assay. Serum samples 
were diluted 1:5 or 1:10 with PBS. Serial dilutions of Wako cholesterol standard 
were used to establish a standard concentration curve. Wako cholesterol oxidase 
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reagent was added to the wells to create an optically active compound. Wells 
were then heated at 37º C for 5 minutes before being assayed in a Molecular 
Devices Spectramax M3 using Softmax Pro 6.3 software. Absorbance was 
measured at 600nm against a background of 700nm. All samples were run in 
duplicate. 
 Serum triglyceride levels were assayed in a similar manner as described 
for the serum cholesterol assay. Infinity triglyceride standard and Infinity reagent 
were used and the calculation of absorbance was at 500nm against a 600nm 
background. 
Cholesterol and triglyceride absorbance data from Softmax Pro 6.3 were 
copied into Microsoft Excel. Background absorbance values were subtracted 
from the active absorbance wavelengths. The duplicate well sample values were 
averaged and the values of the standard series for each plate were graphed on a 
scatter plot to calculate a line of best fit. Using the trend line equation of the 
standard curve, concentration values of each sample were calculated. Sample 
concentration values obtained in this way were multiplied by the original dilution 
ratio to return results in units of mg/dL. 
 
Antibody Assays Following Immunization 
 ApoB-100 was diluted with PBS, added to wells, and incubated at 4° C 
overnight to coat the wells. The plate was washed with PBS-Tween in between 
steps. Goat serum was used for blocking. Plasma serum samples were added 
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and incubated for 2 hours. Either goat anti-mouse IgM µ chain biotinylated 
antibodies (Jackson) or goat anti-mouse IgG Fcγ fragment biotinylated (Jackson) 
were added as detection antibodies. Streptavidin conjugated with alkaline 
phosphatase was added to bind to the antibodies. P-nitrophenyl phosphate was 
used as a substrate and NaOH was used to stop the reaction. Absorption was 
measured at 405nm against a 570nm background. 
 
Kidney Histology 
Kidneys were harvested from the mice at the time of sacrifice, bisected, 
stored in tissue cassettes, and fixed in 10% neutral-buffered formalin for at least 
24 hours. Kidneys were dehydrated by immersion in a series of ethanol solutions. 
Ethanol was cleared from the tissues by processing in a series of xylene 
solutions. Tissues were heated at 58º C and infiltrated with TissuePrep paraffin 
wax. A Sakura Tissue-Tek embedding machine was used to embed kidney 
tissues in molten paraffin wax that was then cooled into blocks. A Leica RM2135 
microtome was used to cut the blocks into 6 µM sections mounted on ColorFrost 
Plus charged slides. Slide sections were heated at 58º C, washed in a series of 
xylene and ethanol to remove paraffin, and then stained using hematoxylin and 
eosin.  
Photomicrographs were captured at 40x objective magnification using an 
Olympus BX41 microscope and MagnaFire-SP software. Image analysis was 
performed using Adobe Photoshop CS5 on Windows 7 and Adobe Photoshop 
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CS6 on Mac OSX. The glomerular tuft size was assessed, (n=30) per mouse, by 
use of the pixel selection and image analysis tools in Adobe Photoshop. Slides 
were analyzed by a researcher blinded to their identity. 
  
Statistical Analyses 
  Results are shown as the mean ± SEM. A Student’s T-Test was used to 
compare the different treatment groups. Results with P < 0.05 were considered 
statistically significant. 
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RESULTS 
Serum Cholesterol Concentrations Were Calculated from the Absorbance 
of a Cholesterol Standard Assayed Simultaneously with Samples 
 Serial dilutions of cholesterol standard were created to establish a dilution 
curve (Table 1 and Figure 1). Absorbance values from these standards were 
plotted and the trend line equation was used to calculate the cholesterol 
concentration in the serum samples. 
 
Table 1: Cholesterol standard concentrations 
Cholesterol Standards Plate 1    
Concentration 
(mg/dL)  
Assay 1 Assay 2 Average 
200 0.71 0.83 0.77 
100 0.42 0.41 0.41 
50 0.21 0.19 0.20 
25 0.11 0.11 0.11 
12.5 0.06 0.05 0.05 
6.25 0.03 0.03 0.03 
3.125 0.02 0.02 0.02 
0 0.01 0.01 0.01 
 
Figure 1: Cholesterol standard curve 
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Treatment with apoB-100 Peptide Vaccine Does Not Affect Serum 
Cholesterol 
A statistically significant difference of serum triglyceride levels was 
observed in the gld.apoE-/- mice between the Alum and the apoB-100 treatment 
groups. Outside of this finding, neither serum cholesterol nor serum triglyceride 
levels showed statistically significant differences between treatment groups in 
apoE-/-, gld, or gld.apoE-/- mice (Table 2 and Figure 2). The hypercholesterolemic 
apoE-/- phenotype had roughly an order of magnitude higher average serum 
cholesterol than the gld or the gld.apoE-/- mice. Gld.apoE-/- mice cholesterol was 
moderately higher than gld mice as expected.  
Within the apoE-/- treatment groups, Alum had the highest cholesterol 
concentration and the PBS control group had the lowest. In gld mice, Alum and 
apoB-100 treated mice had similar levels of cholesterol with the PBS group 
displaying slightly higher levels. The gld.apoE-/- apoB-100 treatment group had 
the highest cholesterol, the alum had the lowest, and the PBS group was 
between the other two groups. Taken together, while it appears that apoB-100 
does not have an effect on apoE-/- or gld mice, the effect on gld.apoE-/- could be 
further delineated in a future study.  
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Table 2: Serum cholesterol  
Phenotype/Treatment Group Serum Cholesterol (mg/dL) 
apoE-/- PBS 766.8 ± 26.4 
apoE-/- Alum 833.9 ± 33.5 
apoE-/- apoB-100 811.4 ± 24.4 
gld PBS 79.9 ± 20.7 
gld Alum 73.4 ± 11.7 
gld apoB-100 72.3 ± 10.9 
gld.apoE-/- PBS 119.2 ± 4.8 
gld.apoE-/- Alum 111.1 ± 6.4  
gld.apoE-/- apoB-100 133.2 ± 9.1  
 
 
Figure 2: Serum cholesterol concentration does not change with apoB-100 
immunization. Total cholesterol levels were measured by colorimetric assay 
from serum obtained at study endpoint for (A) apoE-/- (n=19, 19, 20), (B) gld 
(n=20, 19, 20), and (C) gld.apoE-/- mice (n=15, n=18, n=18) for PBS, Alum, and 
apoB-100 respectively.  
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Immunization with apoB-100 Peptide Does Not Affect Serum Triglyceride 
Levels 
 The plates used to assay serum triglyceride had serial dilutions of 
triglyceride standard arranged in a similar fashion as the cholesterol plates. From 
the standards the concentration of triglyceride in the serum samples was 
calculated. 
ApoE-/- mouse triglyceride levels were about double those of gld mice 
(Table 3 and Figure 3). The triglyceride concentration of ApoE -/- mice was tightly 
clustered among the treatment groups, whereas gld mice receiving Alum were 
slightly higher compared to PBS and apoB-100. Gld.apoE-/- triglyceride averages 
for the PBS and alum groups were centered halfway between the apoE -/- and gld 
mice, with the exception of the apoB-100 treatment group, which was close to the 
levels of the apoE -/- mice. The increase in serum triglyceride levels in gld.apoE-/- 
mice after immunization was significant compared to Alum treatment (p=0.03) but 
not when compared to PBS treatment (p=0.11).  
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Table 3: Serum triglyceride concentrations 
Phenotype/Treatment 
Groups 
Serum Triglyceride (mg/dL) 
apoE-/- PBS 145 ± 20.7 
apoE-/- Alum 141 ± 27.0 
apoE-/- apoB-100 138.5 ± 21.7 
gld PBS 61.5 ± 18.6 
gld Alum 73.4 ± 17.1 
gld CVX 64.8 ± 19.8 
gld.apoE-/- PBS 99.1 ± 5.9 
gld.apoE-/- Alum 89.2 ± 6.7 * 
gld.apoE-/- apoB-100 133.6 ± 11.6 * 
  * P=0.03 for gld.apoE-/- Alum vs. gld.apoE-/- apoB-100 
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Figure 3: Serum triglyceride levels trend towards increase in gld.apoE-/- 
mice after apoB-100 immunization. Total triglyceride levels (mg/dL) were 
measured by colorimetric assay from serum obtained at study endpoint for (A) 
apoE-/- (n=19, 19, 20), (B) gld (n=20, 19, 20), and (C) gld.apoE-/- mice (n=15, 18, 
18) for PBS, Alum, and apoB-100 respectively.  
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Initial Antibody Response to Immunization with apoB-100 Diminishes Over 
Time  
Across phenotypes and treatment groups, antibody titers were significantly 
higher at the midpoints than at the endpoints. This might be expected, since the 
midpoint samples were obtained closer to the time of immunization (Table 4).. 
Within specific phenotypes, differences between treatment groups were not 
statistically significant. At the time of this thesis the gld.apoE-/- cohort had not 
been completed and their antibody response was not able to be included. 
 
Table 4: apoB-100 ELISA performed at midpoint and endpoint 
 Midpoint Endpoint 
  IgM IgG IgM IgG 
apoE-/- PBS 3.37 ± 0.14 0.73 ± 0.19 2.60 ± 0.19 0.47 ± 0.05 
apoE-/- Alum 3.34 ± 0.15 1.27 ± 0.47 2.37 ± 0.19 0.47 ± 0.06 
apoE-/- ApoB-100 3.29 ± 0.14 0.90 ± 0.24 2.38 ± 0.22 0.38 ± 0.04 
gld PBS 3.29 ± 0.14 1.28 ± 0.19 3.20 ± 0.19 2.75 ± 0.26 
gld Alum 3.78 ± 0.11 1.37 ± 0.53 3.34 ± 0.20 2.78 ± 0.27 
gld ApoB-100 3.23 ± 0.15 1.46 ± 0.22 3.61 ± .012 3.14 ± 0.20 
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Glomerular Tuft Size as a Measure of Autoimmune Renal Disease 
Renal disease is a common consequence of lupus pathogenesis. By 
examining morphologic changes in the kidney in an autoimmune model, the 
extent of autoimmune disease can be assessed. Increased glomerular tuft size is 
indicative of more severe renal disease in the gld and gld.apoE-/- autoimmune 
phenotypes. 
Among gld mice, there was no significant difference in glomerular tuft size 
regardless of treatment. Average glomerular tuft area was 28,470 ± 1585; 25,514 
± 1373; and 28,391 ± 1664 pixels for PBS, Alum, and apoB-100 treatment 
groups, respectively (Figure 4). The lack of a statistically significant difference 
between treatment groups and controls in this study suggests that treatment with 
apoB-100 neither improved nor worsened autoimmune-related renal disease in 
these mice. 
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Fig 4: Glomerular tuft size of gld mice. Arrows indicate glomerular tufts. 
Representative photomicrographs of H&E stained kidney sections from gld mice 
receiving subcutaneous injections of (A) PBS (n=20), (B) Alum (n=19), or (C) 
apoB-100 (n=20). 400x magnification. 
 
Among gld.apoE-/- mice, Alum treatment to mice receiving either normal 
chow trended towards an increase in glomerular tuft size (Figure 5). Gld.apoE-/- 
mice fed a normal diet had an average glomerular tuft area of 36713.5 ± 1746; 
40,095 ± 2263; and 37,092 ± 1912 pixels, for PBS, Alum, and apoB-100 
treatment respectively. Western diet groups in general had larger tuft areas with 
the exception of the apoB-100 treatment group, which displayed a smaller 
average tuft area when fed Western diet. Gld.apoE-/- mice fed a Western diet had 
an average glomerular tuft area of 40,574± 1536; 44,933 ± 2004; and 35,482 ± 
1909 pixels, for PBS, Alum, and apoB-100 treatment respectively. None of the 
differences between these groups were statistically significant. 
Overall, average glomerular tuft sizes reflected the severity of autoimmune 
disease in each phenotype, with gld.apoE-/- tufts being larger on average than gld 
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tufts, but no statistically significant differences were observed among treatment 
groups within phenotypes. 
 
 
	  
 
Fig 5: Glomerular tuft size of gld.apoE-/- mice maintained on normal chow 
or Western diet. Arrows indicate glomerular tufts. Representative 
photomicrographs of H&E stained kidney sections from gld.apoE-/- mice 
maintained on (A-C) normal chow or (D-F) Western diet, and receiving 
subcutaneous injections of PBS (A,D; n= 8, 4), Alum (B,E; n= 10, 5), or apoB-
100 (C,F; n= 9, 6). 400x magnification   
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DISCUSSION 
ApoB-100 Immunization Did Not Adversely Affect gld or gld.apoE-/- Mice 
In toto, the procedures performed during this study indicated that apoB-
100 immunization neither improved nor worsened autoimmune sequela. The 
antibody response to immunization was gauged via ELISA for specific IgG and 
IgM antibodies. Serum cholesterol and triglyceride absorbance did not show 
significant differences between treatment groups, with the single exception of 
gld.apoE-/- Alum and apoB-100 treatment groups. Autoimmune disease severity 
was examined through measurement of glomerular tuft size, and no significant 
differences were found between treatment groups. The paucity of statistically 
significant changes either in a positive or a negative direction following 
immunization suggest that the modulation of the immune response using apoB-
100 has neither a beneficial nor an adverse effect in the gld or gld.apoE-/- 
models. This is promising insofar as it does not invalidate the possibility of 
utilizing such a vaccination therapy in a lupus setting. 
The observation of lower serum cholesterol in gld.apoE-/- mice compared 
to apoE-/- mice reflects results from previous papers using the phenotypes 
(Aprahamian, 2004) (Aprahamian, 2006). The lack of statistically significant 
differences between serum cholesterol and serum triglyceride in apoE-/- is in line 
with previous studies investigating apoB-100 immunization (Chyu, 2005) 
(Wigren, 2011). In the 2005 study, both the highest serum cholesterol and the 
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greatest reduction in atherosclerotic disease were seen in the apoE-/- apoB-100 
treatment group.  
Of note, the cholesterol and triglyceride values for the gld mice were not 
significantly different between treatment groups. It is a viable concern that 
immunization could have an adverse effect on serum levels of either in the 
autoimmune model. Taking into consideration that oxLDL is elevated in SLE 
patients, this is a promising indicator for the tolerance of this particular 
immunization in an autoimmune environment. Similarly, as increased glomerular 
tuft size is indicative of more severe renal disease in the gld and gld.apoE -/- 
autoimmune phenotypes, the lack of a statistically significant difference between 
treatment groups and controls suggests that treatment with apoB-100 neither 
improved nor worsened autoimmune-related renal disease in these mice. Taken 
together, these findings do not demonstrate immediately obvious problems with 
apoB-100 immunization in a lupus model, which leaves the door open for further 
exploration of its applicability for SLE patients. 
 
Potential Consequences of Anti-Atherosclerosis Immunization in SLE 
Patients 
 One potentially complicating aspect of the prospective immunization using 
apoB-100 related peptide in the context of an SLE disease background is the 
preexisting presence of anti-oxLDL antibodies in SLE patients. OxLDL levels are 
elevated in SLE patients and are associated with cardiovascular and renal 
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disease (Frostegård, 2005). SLE patients also have elevated levels of oxLDL-
β2GPI complexes (β2GPI binds to oxLDL but not its non-oxidized form) and the 
IgG antibodies against these complexes have been suggested to contribute to 
atherosclerotic risk in SLE (Lopez, 2003). 
Whether the role of anti-oxLDL antibodies is atherogenic or 
atheroprotective is incompletely understood. Studies of SLE patients examining 
the relationship between anti-oxLDL antibody levels and carotid intima-media 
thickness (cIMT) have been further complicated by the multifarious types of 
oxLDL. Antibodies binding to MDA-LDL are inversely correlated between IgM 
antibodies to MDA-LDL and cIMT (Karvonen, 2003). Further research has shown 
that antibodies binding to oxLDL-β2GPI-complexes are positively correlated 
between cIMT and IgM and IgG anti-oxLDL-β2-GPI antibodies (Nowak, 2012). 
That SLE patients have higher levels of IgG antibodies to the oxLDL-β2-GPI 
complexes than healthy controls (Lopez, 2003) speaks to the complications and 
risks that lupus poses to the prospect of immunomodulatory treatment. It is 
conceivable that immunization with apoB-100 could be well tolerated by the 
general population yet some antibody-mediated aspect of its mechanism of 
action might hold risks unique to SLE patients. 
 
Regulatory T Cells as Potential Mechanism of Action of apoB Peptide 
Based Vaccination 
	  29 
 The observation that immunization with an apoB p210 peptide led to a 
reduction of atherosclerosis without mounting an antibody response (Fredrikson, 
2008) prompted further exploration of other components of the immune system 
that could potentially be involved in its immunomodulatory mechanism. One such 
component is the regulatory T cell (Treg) population. Specifically, Treg cells are 
FoxP3+ CD4+ CD25+ T cells, with the expression of FoxP3+ transcription factor 
delineating them from CD4+ CD25+ effector T cells. T cell autoreactivity is 
necessary for the body to combat pathogens that display similarity to self-
antigens, but this must be balanced. Control over the extent of self-reactivity is 
exerted at several stages of T cell maturation including during development in the 
thymus where they are tested against MHC and self-antigens. This selects for T 
cells with a “goldilocks” amount of self-recognition (not too much, not too little) 
but is not an error-proof process. After maturation and release from the thymus 
into the periphery, T cells are subject to downregulation by Treg cells 
(Sakaguchi, 2000).  
Regarding their potential atheroprotective role, depletion of Treg cells in 
mice was shown to worsen atherosclerotic lesions (Ait-Oufella, 2006). Deletion of 
FoxP3+ also worsens atherosclerosis as well as hypercholesterolemia 
(Klingenberg, Gerdes, 2013). In contrast, Treg cells transferred into mice 
lessened the development of atherosclerotic lesions (Mallat, 2003). There are 
also some incipient findings that Treg cells might have analogous functionality in 
humans. Human patients with acute coronary syndrome were found to have 
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markedly decreased levels of FoxP3+ Tregs (Cheng, 2008). Tissue samples from 
patients undergoing vascular surgery and at autopsy showed that FoxP3+ cells 
were less prevalent at sites of atherosclerotic lesions (De Boer, 2007). However, 
no clinical studies have linked Tregs to future atherosclerotic risk, making the 
results of the animal studies promising yet not conclusive.  
 In a study investigating the possible involvement of Tregs in the apoB 
p210 vaccine mechanism, the T cell population of immunized mice had a higher 
proportion of CD4+ spleen cells expressing FoxP3+ than control mice (Wigren, 
2011). Immunized mice were also found to have higher levels of IL-10 (an anti-
inflammatory cytokine) as well as a lower proportion of CD25+ effector cells. 
Crucially, the administration of CD25+ antibodies lowered the FoxP3+ count and 
reversed the atheroprotective effects of immunization in mice treated with apoB 
p210. (The possibility that a CD25+ effector response was responsible for the 
efficacy of apoB p210, and that this was inhibited by the antibodies, was 
discounted by the authors on the basis of multiple prior studies unambiguously 
identifying Th1 CD25+ cells as proatherogenic.) That the administration of CD25+ 
antibodies also lowered IL-10 levels raises the possibility that the secretion of 
that cytokine may be part of the mechanism by which FoxP3+ modulates the 
immune response in atherosclerosis. An increase in FoxP3+ cells in lymph 
nodes, as well as reductions in atherosclerosis, proatherogenic T cells and their 
cytokines, was observed in response to apoB p210 as well as other apoB related 
peptides administered via continuous subcutaneous delivery (Herbin 2012).  
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Dendritic Cells as Potential Mechanism of Action of apoB Peptide Based 
Vaccination 
 Dendritic cells (DCs) are involved in both the innate and adaptive immune 
systems. In their capacity as agents of the adaptive immune system, DCs are 
responsible for presenting antigens to T cells. They permeate the body in 
“immature” form, unable to activate T cells. After taking up antigens and forming 
a MHC complex, they travel to lymph nodes and the spleen where they complete 
the maturation process. Once there, DCs are able to influence T cells to launch 
immune responses or to maintain self-tolerance. When upregulating an immune 
response, DCs direct the expansion of Th1 populations as well as natural killer T 
cells (Maldonado-López, 1999) (Homann, 2002). In addition, DCs upregulate 
transforming growth factor beta (TGF-β) and IL-10 to induce T cell tolerance, 
(Akbari, 2002). The control that dendritic cells wield over the fate of T cells has 
made them a target of investigation in immunomodulatory therapy. 
 Treatment of DCs with the immunosuppressive cytokine IL-10 has shown 
promise in terms of altering the immune response of treated animals. Pulsing 
DCs with IL-10 in vitro was found to reduce several inflammatory cytokines, 
including IFN-γ, IL-4, and IL-5 (Bellinghausen, 2001). Susceptibility to IL-10 
treatment is specific only to immature DCs (Jonuleit, 2000). Intriguingly, a similar 
pulsing technique with DCs using TGF-β was able to upregulate FoxP3+ Treg 
cells (Luo, 2007). 
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 Narrowing the focus to the treatment of atherosclerosis, DCs specialized 
to the arterial intima and belonging to the overall immunological milieu of T cells 
and other monocytes have been identified (Waltner-Romen, 1998). 
Atherosclerosis-prone regions of the intima were found to have more DCs than 
atherosclerosis-resistant areas (Lord, 1999). The introduction of DCs pulsed with 
MDA-LDL into apoE-/- mice worsened atherosclerotic disease, implying that their 
response to oxLDL may help mediate the inflammatory response in 
atherosclerosis (Hjerpe, 2010). 
Given the studies elucidating the changes apoB-100 immunization makes 
on T cell populations and considering the role DCs play on T cell fate, 
investigating DCs in relation to the mechanism of apoB-100 could be fruitful. A 
recent study exploring the use of DCs to deliver apoB-100 p210 peptide minus 
any adjuvant found some differences in immune response compared to prior 
studies. Injected DCs loaded with various forms of apoB-100 peptide were 
tracked as they migrated to lymph nodes and were found to remain in an 
immature state, suggesting that these peptides work towards immune tolerance. 
Further study showed variations in ability to control Treg count, IL-10 release and 
IgG antibody response. Also, DC loaded with the p45 and p210 forms of apoB-
100 led to an IgG antibody response. (Pieride, 2013) While differences between 
peptides with and without DC loading were observed, there are a host of other 
factors unrelated to DCs such as the timing of antigen availability that may be 
responsible for those differences. 
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Alternative Methods and Limitations  
Administration of the Alum adjuvant alone to apoE-/- mice has been 
demonstrated to reduce atherosclerosis (Khallou-Laschet, 2006). However, 
although increased p210 IgG antibody and Treg level have been measured in 
apoE-/- mice injected with Alum, no similar changes were seen when wild type 
C57 mice were injected (Wigren, 2011). To further elucidate the specific immune 
modulation occurring with apoB-100 immunization, methods of administration 
other than injection could be useful. 
One such method recently tested was the intranasal administration of 
apoB-100 p210 protein combined with cholera toxin (CTB), which contains an 
antigen useful for respiratory tract uptake of the complex (Klingenberg, Lebens, 
2010). Immunization in this manner led to a 35% decrease in atherosclerotic 
lesion size as compared to ovalbumin complexed to CTB or controls. As a 
mechanism, the authors suggest that IL-10 secreted by Tregs suppresses T 
effector cells specific for apoB-100. The two candidate Treg populations 
suspected were FoxP3+ induced Treg and Tr1 cells. Tr1 cells are a population of 
Treg cells distinguished by their pronounced secretion of the anti-inflammatory 
cytokines IL-10 and TGF-β as well as their maturation outside the thymus in an 
IL-10-dependent process (Roncarolo, 2006). FoxP3+ Treg cells were ruled out as 
the atheroprotective agent because of the reliance of FoxP3+ on TGF-β signaling. 
Even when researchers eliminated TGF-β signaling, the atheroprotective effect of 
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immunization was maintained, although they note this does not exclude FoxP3+ 
cells from playing a part in activating Tr1 cells.  
 The wealth of information from animal studies investigating the 
relationship between oxLDL and atherosclerosis has made strides in establishing 
how oxidatively modified LDL and antibodies against it contribute to 
atherosclerotic disease. However, a clear understanding of the specific 
mechanism by which oxLDL contributes to atherosclerosis in humans remains 
elusive. Animal and in vivo studies have illustrated several pathways by which 
oxLDL can drive towards a pathogenic state, posing the challenge of identifying 
which are active in the progression of human disease. The incomplete 
understanding is partially due to uncertainty over the extent of homology in 
oxidative modifications to LDL between animals and humans. Previous studies 
on the apoB-100 vaccine have found that the antibodies generated against the 
p210 peptide do not cross react with human native or modified LDL (Chyu, 
2005). This reflects the uncertainty about which specific modified LDL epitope 
generates an immune response in the natural course of the disease.  
Further uncertainty stems from the genetic diversity inherent in the 
immune responses to modified LDL, first observed in animals and subsequently 
explored in humans (Shi, 2000) (Gargalovic, 2006). Over a thousand genes 
expressed by endothelial cells in humans have been found to be upregulated by 
oxLDL. Systems genetics testing of the endothelial cells of heart transplant 
donors revealed widely differential sensitivity among individuals to the effects of 
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oxidation by one particular modified LDL epitope (Romanoski, 2011). The range 
of genetic variation in immune response to just one epitope underscores the 
amount of work needed to untangle the atherosclerotic immune response 
pathway, especially in the context of attempting to modulate the pathway through 
immunization. 
 In conclusion, although the hypothesized reduction in autoimmune 
disease severity in immunized mice was not observed in this study, neither was 
there an observed worsening in autoimmune disease severity. The 
characteristics of the mouse phenotypes tested, namely hypercholesterolemia 
and lupus-like autoimmunity, were not significantly impacted by the immunization 
therapy. Assessments of atherosclerotic disease markers were not performed, 
but if similar reductions in atherosclerotic disease progression were seen after 
immunization in these models as seen in prior studies, it would show promise for 
the potential future treatment of atherosclerotic disease in SLE patients. Clinical 
efficacy of immunization against atherosclerosis is yet to be tested. If 
immunization is found to be clinically feasible, it may represent a novel treatment 
for atherosclerosis and cardiovascular disease in SLE patients. 
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